Cancer immunotherapy approaches, including monoclonal antibodies (mAbs), peptides, adoptive cell transfer, tumor-infecting viruses, cytokines, checkpoint inhibitors, Stimulator of Interferon Genes (STING), and Toll-Like Receptor (TLR) agonists, have been developed to induce robust antitumor immune responses [4] (This Ref from Dr.Nojoud Part). The gene discussed is STING1; the disease is cancer.